Cetyl-Myristoleate Information and Uses

Cetyl-Myristoleate, also known as CMO or CM, was discovered by Harry W. Diehl, a researcher at the National Institutes of Health working alone in his home lab. Diehl took a fatty acid, myristoleic acid, and combined it with the fatty alcohol molecule cetyl alcohol, creating an ester of that fatty acid called cetyl myristoleate. He discovered that it was the presence of this compound in Swiss albino mice that prevented them from developing joint problems. Diehl's laboratory experiments on CM were published in the Journal of Pharmaceutical Sciences in March, 1994.

It is believed that CMO acts as a type of joint lubricant and anti-inflammatory agent. Based on animal studies and several human case histories, CMO is now believed to be a useful and an effective remedy for both osteoarthritis and rheumatoid arthritis. In a double-blind study, 106 people with different types of arthritis who had failed to respond to non-steroidal anti-inflammatory drugs received cetyl myristoleate (540 mg per day orally for 30 days), while 226 others received a placebo. These people also applied cetyl myristoleate or placebo topically, according to their perceived need. Some 63.5 of those receiving cetyl myristoleate improved, compared with only 14.5 of those receiving the placebo. (Siemandi H. The effect of cis-9-cetyl myristoleate (CMO) and adjunctive therapy on arthritis and auto-immune disease: a randomized trial. Townsend Letter for Doctors and Patients 1997;(Aug/Sept):58-63.)


It has been suggested that CMO be taken in dosages of 400 to 500 mg daily for 30 days.

Note: Claims for this substance have been sweeping based upon an isolated finding that it provides protection against adjuvant-induced arthritis in animal subjects. Until further positive research results are obtained from well-designed and executed clinical trials, the human use of cetyl myristoleate supplements cannot be substantiated.